Thrombotic Risk Stratification in CAD Patients
Stratify thrombotic risk in CAD patients using a combination of clinical and procedural features, with high thrombotic risk defined as the presence of at least one clinical criterion plus one procedural criterion, which identifies approximately 25-30% of patients at significantly elevated risk for major adverse cardiovascular events. 1, 2
Clinical Risk Criteria for High Thrombotic Risk
The following clinical features identify patients at elevated thrombotic risk 1:
- Prior myocardial infarction - particularly relevant in patients with recurrent events 2
- Multivessel coronary artery disease - especially with complex anatomy 1, 3
- Diabetes mellitus requiring medication 1
- Chronic kidney disease (eGFR <60 mL/min/1.73m²) 1
- Prior stroke or transient ischemic attack 1
- Peripheral artery disease 1
- Heart failure or reduced left ventricular ejection fraction (<40%) 1
Procedural Risk Criteria for High Thrombotic Risk
When patients undergo percutaneous coronary intervention, these procedural features elevate thrombotic risk 1, 3:
- Complex PCI - including bifurcation lesions requiring two-stent technique, total occlusion, or left main intervention 3
- Stent thrombosis as the presenting event 3
- Three or more stents implanted 1
- Three or more lesions treated 1
- Total stent length >60 mm 1
Risk Stratification Categories and Outcomes
Patients should be categorized into three risk groups based on annual cardiovascular death or nonfatal MI risk: 1
- Low risk: <1% annual event rate - typically patients with no or one isolated risk factor 1
- Moderate risk: 1-3% annual event rate - patients with multiple risk factors but not meeting high-risk criteria 1, 2
- High risk: >3% annual event rate - patients meeting both clinical and procedural high-risk criteria 1, 2
The high thrombotic risk definition successfully identifies patients with approximately 1.85-fold increased risk of major adverse cardiovascular events at one year compared to low-to-moderate risk patients 2. In real-world registries, high-risk patients experience MACE rates of 23.3% versus 13.6% in lower-risk groups 2.
Additional Prognostic Markers
Beyond clinical and procedural criteria, incorporate these advanced risk markers when available: 1
- Imaging-based risk features: High coronary calcium score, reduced coronary flow reserve (<2), transient ischemic dilation on SPECT, high-risk plaque features on CCTA (positive remodeling, low attenuation, napkin-ring sign), reduced CT-fractional flow reserve 1
- Functional testing results: Duke Treadmill Score, exercise capacity, peak rate-pressure product <15,000 1
- Biomarkers: High-sensitivity troponin elevation, B-type natriuretic peptide 1
Critical Caveats
The predictive ability of current thrombotic risk criteria is modest (C-index 0.60), meaning these tools successfully stratify patients into risk categories but have limited precision for individual prediction. 4 This underscores the importance of using risk stratification as a guide rather than an absolute determinant, particularly when deciding on extended dual antiplatelet therapy duration 4.
Avoid the common pitfall of focusing solely on anatomic severity - hemodynamic significance (FFR ≤0.80) and functional testing results provide critical prognostic information beyond angiographic appearance alone 1, 5.
In patients with atrial fibrillation requiring oral anticoagulation, thrombotic risk stratification must be balanced against bleeding risk, as this population requires modified antithrombotic strategies with shorter or no antiplatelet therapy duration 1.